Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in contrast with imatinib, for the initial-line treatment method of CML-CP. 5 hundred and nineteen clients with freshly diagnosed CML-CP were randomly assigned to obtain dasatinib at a dose of 100 mg when day by day (259 clients) or https://sergiolrwdg.spintheblog.com/29097196/epiberberine-options